XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.
Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.
DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.
XtalPi (2228.HK) e DoveTree Medicines hanno annunciato una collaborazione strategica rivoluzionaria da 6 miliardi di dollari nel campo della scoperta di farmaci guidata dall'intelligenza artificiale. La partnership unisce la piattaforma di AI e robotica di XtalPi con l'expertise biologica di DoveTree per sviluppare nuovi trattamenti in diverse aree terapeutiche.
Secondo l'accordo, DoveTree ottiene diritti esclusivi a livello globale e verser脿 a XtalPi un pagamento iniziale di 51 milioni di dollari, con ulteriori 49 milioni di dollari in pagamenti a breve termine e fino a 5,89 miliardi di dollari in pagamenti legati a milestone e royalty a scaglioni. La collaborazione si concentrer脿 sullo sviluppo di candidati innovativi in oncologia, immunologia, infiammazione, neurologia e malattie metaboliche.
DoveTree, fondata dal rinomato sviluppatore di farmaci Dr. Gregory Verdine, porta la sua esperienza nel rendere 鈥渇armacologicamente attaccabili鈥� bersagli considerati fino ad ora non trattabili, mentre XtalPi contribuisce con la sua piattaforma intelligente di scoperta di farmaci de novo che copre diverse modalit脿, tra cui piccole molecole, biologici, ADC e molecular glues.
XtalPi (2228.HK) y DoveTree Medicines han anunciado una colaboraci贸n estrat茅gica revolucionaria valorada en 6 mil millones de d贸lares para el descubrimiento de f谩rmacos impulsado por inteligencia artificial. La asociaci贸n combina la plataforma de IA y rob贸tica de XtalPi con la experiencia biol贸gica de DoveTree para desarrollar nuevos tratamientos en m煤ltiples 谩reas terap茅uticas.
Seg煤n el acuerdo, DoveTree recibe derechos exclusivos a nivel mundial y pagar谩 a XtalPi un pago inicial de 51 millones de d贸lares, con 49 millones de d贸lares en pagos a corto plazo y hasta 5.89 mil millones de d贸lares en pagos por hitos y regal铆as escalonadas. La colaboraci贸n se centrar谩 en desarrollar candidatos innovadores en oncolog铆a, inmunolog铆a, inflamaci贸n, neurolog铆a y enfermedades metab贸licas.
DoveTree, fundada por el reconocido desarrollador de f谩rmacos Dr. Gregory Verdine, aporta su experiencia en 鈥渕edicar lo no medicable鈥�, mientras que XtalPi contribuye con su plataforma inteligente de descubrimiento de f谩rmacos de novo que abarca m煤ltiples modalidades, incluidas peque帽as mol茅culas, biol贸gicos, ADC y molecular glues.
XtalPi (2228.HK)鞕赌 DoveTree Medicines臧� AI 旮半皹 鞁犾暯 臧滊皽 攵勳暭鞐愳劀 60鞏� 雼煬 攴滊鞚� 須嶊赴鞝侅澑 鞝勲灥鞝� 順戨牓鞚� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 韺岉姼雱堨嫮鞚� XtalPi鞚� AI 氚� 搿滊炒韹膘姢 頂岆灚韽缄臣 DoveTree鞚� 靸濍頃欖爜 鞝勲 歆�鞁濎潉 瓴绊暕頃橃棳 雼れ枒頃� 歆堧硲 鞓侅棴鞐愳劀 順侅嫚鞝侅澑 旃橂鞝滊ゼ 臧滊皽頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
瓿勳暯鞐� 霐半澕 DoveTree電� 鞝� 靹戈硠 霃呾爯 甓岆Μ毳� 須嶋摑頃橂┌, XtalPi鞐� 5,100毵� 雼煬鞚� 靹犽秷旮�鞚� 歆�旮夗晿瓿�, 雼赴鞝侅溂搿� 4,900毵� 雼煬鞚� 於旉皜 歆�旮夑臣 斓滊寑 58鞏� 9觳滊 雼煬鞐� 雼晿電� 毵堨澕鞀ろ啢 歆�旮� 氚� 雼硠氤� 搿滌棿韹半ゼ 歆�旮夗晿瓴� 霅╇媹雼�. 鞚措矆 順戨牓鞚� 鞎�, 氅挫棴頃�, 鞐检, 鞁犼步頃� 氚� 雽�靷� 歆堩櫂 攵勳暭鞐愳劀 順侅嫚鞝侅澑 頉勲炒 氍检 臧滊皽鞐� 歆戩頃� 鞓堨爼鞛呺媹雼�.
DoveTree電� 鞙犽獏 鞁犾暯 臧滊皽鞛� Dr. Gregory Verdine臧� 靹る頄堨溂氅�, '旃橂臧� 鞏措牑鞖� 響滌爜鞚� 鞎诫搿� 瓿惦灥頃橂姅' 鞝勲 歆�鞁濎潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟. XtalPi電� 靻岆秳鞛�, 靸濍頃欖爜 鞝滌牅, ADC 氚� 攵勳瀽 鞝戩癌鞝� 霌� 雼れ枒頃� 氚╈嫕鞚� 歆�電ロ槙 鞁犾暯 臧滊皽 頂岆灚韽检潉 鞝滉车頃╇媹雼�.
XtalPi (2228.HK) et DoveTree Medicines ont annonc茅 une collaboration strat茅gique r茅volutionnaire de 6 milliards de dollars dans la d茅couverte de m茅dicaments assist茅e par intelligence artificielle. Ce partenariat combine la plateforme d'IA et de robotique de XtalPi avec l'expertise biologique de DoveTree pour d茅velopper de nouveaux traitements dans plusieurs domaines th茅rapeutiques.
Dans le cadre de cet accord, DoveTree obtient des droits exclusifs mondiaux et versera 脿 XtalPi un paiement initial de 51 millions de dollars, avec 49 millions de dollars de paiements 脿 court terme et jusqu'脿 5,89 milliards de dollars en paiements li茅s 脿 des 茅tapes cl茅s et redevances 茅chelonn茅es. La collaboration se concentrera sur le d茅veloppement de candidats innovants en oncologie, immunologie, inflammation, neurologie et maladies m茅taboliques.
DoveTree, fond茅e par le c茅l猫bre d茅veloppeur de m茅dicaments Dr. Gregory Verdine, apporte son expertise dans la 芦 m茅dication des cibles jug茅es inaccessibles 禄, tandis que XtalPi contribue avec sa plateforme intelligente de d茅couverte de m茅dicaments de novo couvrant plusieurs modalit茅s, notamment les petites mol茅cules, les biologiques, les ADC et les colles mol茅culaires.
XtalPi (2228.HK) und DoveTree Medicines haben eine bahnbrechende strategische Zusammenarbeit im Wert von 6 Milliarden US-Dollar im Bereich der KI-gest眉tzten Wirkstoffforschung angek眉ndigt. Die Partnerschaft kombiniert XtalPis KI- und Robotikplattform mit DoveTrees biologischer Expertise, um neuartige Therapeutika in verschiedenen Krankheitsbereichen zu entwickeln.
Im Rahmen der Vereinbarung erh盲lt DoveTree exklusive globale Rechte und zahlt XtalPi eine Anzahlung von 51 Millionen US-Dollar, weitere 49 Millionen US-Dollar in kurzfristigen Zahlungen sowie bis zu 5,89 Milliarden US-Dollar an Meilensteinzahlungen und gestaffelten Lizenzgeb眉hren. Der Fokus der Zusammenarbeit liegt auf der Entwicklung von First-in-Class-Kandidaten in den Bereichen Onkologie, Immunologie, Entz眉ndungen, Neurologie und Stoffwechselerkrankungen.
DoveTree, gegr眉ndet vom renommierten Arzneimittelentwickler Dr. Gregory Verdine, bringt Expertise im Bereich 鈥瀌ie Unangreifbaren angreifbar machen鈥� ein, w盲hrend XtalPi seine intelligente de novo Wirkstoffentdeckungsplattform beisteuert, die verschiedene Modalit盲ten wie kleine Molek眉le, Biologika, ADCs und molekulare Klebstoffe umfasst.
- Massive deal value of $6 billion including $51 million upfront payment and $49 million in near-term payments
- Strategic partnership combines XtalPi's AI technology with DoveTree's biological expertise in multiple therapeutic areas
- Collaboration led by renowned drug developer Dr. Verdine with track record of FDA-approved drugs
- Development targets high-value 'undruggable' proteins with significant market potential
- Long-term milestone payments of $5.89 billion are contingent on development and commercial success
- Complex drug development process targeting challenging mechanisms carries significant technical risks
Insights
XtalPi-DoveTree's $6B AI drug discovery deal represents a transformative investment in AI-driven pharma R&D with significant milestone potential.
This
What makes this partnership particularly compelling is the strategic alignment of complementary strengths. XtalPi contributes its multimodal drug discovery platform integrating quantum physics, AI-driven design, and robotic automation across multiple therapeutic modalities including small molecules, biologics, ADCs, and molecular glues. DoveTree brings Dr. Verdine's expertise in "drugging the undruggable" targets鈥攑articularly significant as the industry increasingly focuses on previously inaccessible disease mechanisms.
The therapeutic focus on oncology, immunology, inflammation, neurology, and metabolic diseases represents high-value, competitive areas with substantial unmet needs and commercial potential. Most notably, the explicit mention of molecular glue technology signals intent to pursue one of the most promising emerging modalities in drug development, capable of addressing traditionally undruggable proteins like RAS, Myc, and 尾-catenin that have long been considered holy grails in therapeutic development.
Dr. Verdine's track record of co-founding multiple successful biopharma companies (including Enanta, Rein, and WaVe) and co-developing three FDA-approved drugs adds substantial credibility to this venture. The scale of investment suggests DoveTree and XtalPi are positioning to build a substantial pipeline rather than focusing on single-asset development, creating multiple paths to potential value creation through this partnership.
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases.
Under the agreement, DoveTree gains exclusive global rights to develop and commercialize a portfolio of innovative therapeutics generated through the partnership. XtalPi has received an upfront payment of
This collaboration merges XtalPi's integrated drug discovery capabilities with DoveTree's deep biological expertise in selecting and validating novel targets of high therapeutic potential. Together, the companies will focus on developing first-in-class candidates across oncology, immunology and inflammatory diseases, neurological disorders, and metabolic dysregulation with significant unmet needs. The partnership will advance DoveTree's selected pipeline of projects targeting historically challenging mechanisms, with plans to expand joint R&D capabilities in emerging modalities like molecular glue.
DoveTree Medicines was founded by Dr. Gregory Verdine, an internationally esteemed scientist, entrepreneur, and seasoned investor in the biopharmaceutical field, with outstanding achievements in both academia and industry. He has co-founded over a dozen biopharmaceutical companies, including more than five publicly listed firms such as Enanta Pharmaceuticals (NASDAQ: ENTA), Rein Therapeutics (NASDAQ: RNTX), and WaVe Life Sciences (NASDAQ: WVE). Credited with originating the "drugging the undruggable" concept, Dr. Verdine has pioneered unique molecular glue and peptide technology platforms, successfully applying them to the drug development against "undruggable" proteins such as RAS, Myc, and 尾-catenin. He has co-developed three FDA-approved drugs, with over a dozen additional candidates currently in clinical development.
XtalPi has developed an intelligent de novo drug discovery platform that spans small molecules, biologics, antibody-drug conjugates (ADCs), and molecular glues. This multimodal capability enables the efficient exploration of parallel drug development approaches against single targets and unlocks broader chemical space. By integrating quantum physics predictions, AI-driven molecular design, and a large-scale robotic lab-in-the-loop, XtalPi significantly accelerates the drug discovery workflow鈥攆rom target analysis and molecular generation to affinity prediction, ADMET assessment, and synthesis design鈥攚ith enhanced accuracy and efficiency. Through extensive partnerships with innovative pharmaceutical companies, XtalPi's platform has been rigorously validated in real-world projects, accumulating vast datasets of standardized experimental data and high-precision computational data to continuously optimize models within a closed feedback loop.
Dr. Gregory Verdine, Founder and Chief Executive Officer of DoveTree, stated: "XtalPi's unique platform has the potential to transform the profound uncertainties of drug discovery into quantifiable engineering solutions. Their demonstrated ability to innovate at scale makes them a valuable partner in pursuing drug targets that are beyond conventional methods. By merging DoveTree's biological insights and extensive R&D expertise with XtalPi's powerful platform, we aim to deliver transformative therapies for patients globally."
Dr. Shuhao Wen, Chairman of XtalPi, commented: "Dr. Verdine and DoveTree bring exceptional biological acumen, business vision, and a proven track record of translational success, perfectly complementing our platform's strengths in high-throughput molecule generation, design, and validation. This partnership positions us to accelerate breakthroughs against complex diseases while expanding the frontiers of AI-driven drug discovery. XtalPi remains committed to advancing our core technologies and working closely with leading innovators to help build diverse pipelines of impactful medicines."
About聽DoveTree Medicines
DoveTree Medicines is a biotech company dedicated to discovering first-in-class medicines for diseases with profound unmet medical needs. Founded and led by distinguished scientist-entrepreneur Dr. Gregory Verdine, DoveTree integrates deep biological insight and advanced AI to unlock novel therapeutic pathways and accelerate the development of transformative medicines, translating pioneering science into meaningful patient benefit.
About XtalPi
XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.
View original content to download multimedia:
SOURCE XtalPi Inc.
FAQ
What is the total value of the XtalPi and DoveTree collaboration agreement?
What therapeutic areas will the XtalPi-DoveTree partnership focus on?
Who is Dr. Gregory Verdine and what is his role in this collaboration?
What technologies does XtalPi's drug discovery platform use?
What are the payment terms of the XtalPi-DoveTree collaboration?
